Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

[1]  K. Owzar,et al.  Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). , 2021, The oncologist.

[2]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[3]  Tao Xi,et al.  RNA-binding proteins in tumor progression , 2020, Journal of Hematology & Oncology.

[4]  Dingxiao Zhang,et al.  RBM38 in cancer: role and mechanism , 2020, Cellular and Molecular Life Sciences.

[5]  Joshua M. Stuart,et al.  Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance , 2020, Proceedings of the National Academy of Sciences.

[6]  A. Nixon,et al.  Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy , 2020, Clinical Cancer Research.

[7]  N. Navin,et al.  Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. , 2019, The Lancet. Oncology.

[8]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[9]  G. E. Fernandez,et al.  Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells , 2019, Clinical Cancer Research.

[10]  Yi Zhao,et al.  Opposing roles and potential antagonistic mechanism between TGF-β and BMP pathways: Implications for cancer progression , 2019, EBioMedicine.

[11]  Ximing J. Yang,et al.  Targeting FOXA1-mediated repression of TGF-&bgr; signaling suppresses castration-resistant prostate cancer progression , 2018, The Journal of clinical investigation.

[12]  D. Owens,et al.  Annual Report to the Nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics , 2018, Cancer.

[13]  C. Theuer,et al.  An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[15]  Zhenqiu Liu,et al.  Heterogeneous cancer associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner , 2018, Oncogene.

[16]  Zhenqiu Liu,et al.  Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming , 2018, The Journal of clinical investigation.

[17]  Eric J Feuer,et al.  Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics , 2018, Cancer.

[18]  Menggang Yu,et al.  Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy , 2017, JAMA oncology.

[19]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Klein,et al.  Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. , 2016, Cancer research.

[22]  S. Plymate,et al.  Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer , 2016, Clinical Cancer Research.

[23]  M. Milowsky,et al.  Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance , 2015, Clinical pharmacology and therapeutics.

[24]  H. Parnes,et al.  A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer , 2015, BJU international.

[25]  S. Steinberg,et al.  A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib , 2015, United European gastroenterology journal.

[26]  Shuang Hou,et al.  Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases , 2015, Cancer.

[27]  M. Gleave,et al.  AR-v7 protein expression is regulated by protein kinase and phosphatase , 2015, Oncotarget.

[28]  R. Cardiff,et al.  Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors , 2014, Proceedings of the National Academy of Sciences.

[29]  Sten Nilsson,et al.  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. , 2014, The Lancet. Oncology.

[30]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[31]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[32]  S. Yeh,et al.  Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver , 2014, Oncogene.

[33]  N. Kyprianou,et al.  Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer , 2014, International journal of biological sciences.

[34]  L. Selth,et al.  Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues , 2014, Hormones and Cancer.

[35]  P. Nelson,et al.  Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer , 2014, Clinical Cancer Research.

[36]  N. Bhowmick,et al.  A reciprocal role of prostate cancer on stromal DNA damage , 2013, Oncogene.

[37]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[38]  D. Bowtell,et al.  The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. , 2013, Cancer cell.

[39]  W. Zhong,et al.  Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies , 2012, PloS one.

[40]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[41]  O. Franco,et al.  Role for stromal heterogeneity in prostate tumorigenesis. , 2011, Cancer research.

[42]  J. Eveson,et al.  TGF-β inhibits metastasis in late stage human squamous cell carcinoma of the skin by a mechanism that does not involve Id1. , 2010, Cancer letters.

[43]  F. Marshall,et al.  Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. , 2010, European urology.

[44]  R. Matusik,et al.  Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. , 2008, Cancer research.

[45]  S. Hayward,et al.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.

[46]  E. Keller,et al.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[48]  B. Brooke,et al.  Defective angiogenesis in mice lacking endoglin. , 1999, Science.

[49]  N. Kyprianou,et al.  Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. , 1999, Cancer research.

[50]  J. Wrana,et al.  Endoglin Is an Accessory Protein That Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β Superfamily* , 1999, The Journal of Biological Chemistry.

[51]  J. Wozney,et al.  Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[53]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[54]  A. Gao,et al.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  N. Kyprianou,et al.  Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. , 1989, Molecular endocrinology.